Chongqing Zhifei Biological Products (300122.SZ): The supplementary application for the influenza virus split vaccine has been accepted.

Chongqing Zhifei Biological Products (300122.SZ) announced that it has recently received a report from its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (referred to as "Zhifei Longcom"). The supplemental application for the influenza virus split vaccine independently developed by Zhifei Longcom has obtained the "Acceptance Notification" issued by the National Medical Products Administration (Acceptance No.: CYSB2600272). Influenza is an acute respiratory infectious disease caused by the influenza virus that can lead to large-scale epidemics. It is highly contagious and can result in complications such as pneumonia, bronchitis, and myocarditis, which can exacerbate underlying conditions in children, increase the disease burden, and pose a threat to human health. Vaccination against influenza is the most economical and effective measure to prevent influenza diseases and outbreaks. Zhifei Longcom's influenza virus split vaccine was approved for market launch in September 2025 and is suitable for individuals aged 3 and older to prevent infectious diseases caused by the influenza virus. This supplemental application adds "children aged 6 to 35 months" to the previously approved population for the influenza virus split vaccine.